Skip to content

Atazanavir approved for first-line treatment in Europe

First-line antiretroviral therapy: not as simple as we'd like it to be

Boosted protease inhibitors have 60% lower risk of resistance compared with other classes

Extensive resistance common in Nigerians failing antiretroviral therapy

Arm of international once-daily treatment study halted

BHIVA: Starting ART earlier has cost implications, public health benefits, says HPA

BHIVA: Many patients and clinicians still need educating about the benefits of treatment

BHIVA: One in 40 people presenting to A&E departments with ‘flu’ symptoms has HIV

BHIVA: Current tests may miss a third of HIV resistance in treatment-naive